Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment
NCT02389231
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
2
Enrollment
OTHER
Sponsor class
Conditions
Autoimmune Hemolytic Anemia
Interventions
DRUG:
Interleukine-2
Sponsor
University Hospital, Bordeaux